Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Passaro, Antonio, Lazzari, Chiara, Karachaliou, Niki, Spitaleri, Gianluca, Pochesci, Alessia, Catania, Chiara, Rosell, Rafael, de Marinis, Filippo
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074703/
https://ncbi.nlm.nih.gov/pubmed/27799783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S98347
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars